Compare Bristol-Myers Squibb Co (BMY) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.54 (market cap $116.30B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $29.12. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| BMY | RDTE | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $34.72 |
52-Week Low | $42.60 | $26.40 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
RDTE trades at $28.72, down 0.62% today, with technical indicators signaling a bearish trend. The stock shows consistent dividend payments but lacks key valuation metrics like P/E and P/S, limiting fundamental clarity. Recent news highlights structural risks in its covered call strategy, which may erode capital over time despite high yield potential.
Outlook remains cautious due to capital erosion risks from its strategy capping upside. Investment opportunity hinges on yield appeal, but risks include NAV deterioration and inability to capture market rallies. Investors should weigh high income against potential long-term value loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
